Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody detects acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins: 67 kDa (CK1); 64 kDa (CK3); 59 kDa (CK4); 58 kDa (CK5); 56 kDa (CK6); 52 kDa (CK8); 56.5 kDa (CK10); 50 kDa (CK14); 50 kDa (CK15); 48 kDa (CK16); 40 kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. It is a broad spectrum anti pan-cytokeratin antibody, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It may be useful to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has high sensitivity in the recognition of epithelial cells and carcinomas.

Flow Cytometry: 0,5 - 1 µg/10e6 cells in 0,1 ml IF: 1 - 2 µg/ml WB: 0,5 - 1 µg/ml IHC (FFPE): 0,25-0,5 µg/ml for 30 min at RT Prediluted format: incubate for 30 min at RT (1) The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the pan Cytokeratin antibody to be titered up or down for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimised for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Type: Primary
Antigen: KRT1, KRT3, KRT4, KRT5, KRT6A, KRT8, KRT10, KRT14, KRT15, KRT16, KRT19
Clonality: Polyclonal
Clone:
Conjugation: Unconjugated
Epitope:
Host: Rabbit
Isotype: IgG
Reactivity: Human